Effects of ezetimibe, either alone or in combination with atorvastatin, on serum visfatin levels: a pilot study

Απλή σελίδα τεκμηρίου
dc.contributor.authorDerdemezis, C. S.en
dc.contributor.authorFilippatos, T. D.en
dc.contributor.authorTselepis, A. D.en
dc.contributor.authorMikhailidis, D. P.en
dc.contributor.authorElisaf, M. S.en
dc.date.accessioned2015-11-24T16:57:18Z
dc.date.available2015-11-24T16:57:18Z
dc.identifier.issn1465-6566-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/10564
dc.rightsDefault Licence-
dc.subjectezetimibeen
dc.subjecthigh-density lipoprotein cholesterolen
dc.subjectlow-density lipoprotein cholesterolen
dc.subjecttriglyceridesen
dc.subjectvisfatinen
dc.subjectdensity-lipoprotein cholesterolen
dc.subjectcolony-enhancing factoren
dc.subjectmetabolic syndromeen
dc.subjectplasma visfatinen
dc.subjectnondiabetic patientsen
dc.subjectphospholipase a(2)en
dc.subjectobeseen
dc.subjecthypercholesterolemiaen
dc.subjectinflammationen
dc.subjectassociationen
dc.titleEffects of ezetimibe, either alone or in combination with atorvastatin, on serum visfatin levels: a pilot studyen
heal.abstractIntroduction: Ezetimibe inhibits intestinal absorption of cholesterol and lowers circulating low-density lipoprotein cholesterol levels. Visfatin is a novel adipokine, which may be implicated in the atherosclerotic process. Objective: The aim of this study was to explore the possible association between ezetimibe administration and serum visfatin concentrations. Methods: Patients (n = 30) with primary dyslipidemia and another 30 who failed to reach their assigned low-density lipoprotein cholesterol target on atorvastatin therapy (20 mg/day) were included in the study. All participants were given ezetimibe at 10 mg/day for 12 weeks. Results: At baseline the visfatin levels correlated significantly with the total cholesterol (r = 0.61 and p < 0.01) and low-density lipoprotein cholesterol (r = 0.51 and p < 0.01) levels in the statin pretreatment group. Furthermore, in the statin group the post-treatment levels of visfatin and low-density lipoprotein cholesterol were significantly correlated (r = 0.57 and p < 0.01). The serum visfatin concentrations did not change significantly in either the monotherapy or statin pretreatment groups or in subgroups divided according to the baseline lipid variables. In both the ezetimibe monotherapy and ezetimibe plus atorvastatin groups the effect of ezetimibe on the lipid variables depended on the baseline lipid values. The low-density lipoprotein cholesterol: high density lipoprotein cholesterol ratio was consistently improved by ezetimibe in all groups or subgroups. Conclusions: Ezetimibe did not alter serum visfatin concentrations, either when administered as monotherapy or combined with a statin. Future studies investigating the effect of ezetimibe on visfatin levels need to include groups of patients with distinct lipid characteristics.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primaryDoi 10.1517/14656560802217671-
heal.identifier.secondary<Go to ISI>://000258276400002-
heal.identifier.secondaryhttp://informahealthcare.com/doi/abs/10.1517/14656566.9.11.1829-
heal.journalNameExpert Opinion on Pharmacotherapyen
heal.journalTypepeer reviewed-
heal.languageen-
heal.publicationDate2008-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείαςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά). ΧΗΜ